Combining other antihypertensive drugs with β-blockers in hypertension: A focus on safety and tolerability

Canadian Journal of Cardiology

Volumn 30, Issue 5 S, 2014, Pages

  Richards, Tiffany R ^a   Tobe, Sheldon W ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEBIVOLOL; VERAPAMIL;

ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRADYCARDIA; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MONOTHERAPY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84899108651     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.08.012     Document Type: Review

References (24)

1. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enyzme inhibitor or calcium channel blocker vs diuretic; the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. [errata in 2004;291:2196; 2003;289:178].
3. Mukherjee D., Fang J., Chetcuti S., Moscucci M., Kline-Rogers E., Eagle K.A. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004, 109:745-749.
4. Hackam D.G., Quinn R.R., Ravani P., et al. The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013, 29:528-542.
5. Hamada T., Watanabe M., Kaneda T., et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. JHypertens 1998, 16:111-118.
6. Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
7. Almenoff J.S., DuMouchel W., Kindman L.A., Yang X., Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003, 12:517-521.
8. Gibson R.S., Boden W.E., Theroux P., et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. NEngl J Med 1986, 315:423-429.
9. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1982, 247:633-638.
10. Stamler J., Neaton J.D., Cohen J.D., et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. JAm Heart Assoc 2012, 1:e003640.
11. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304:405-412.
12. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
13. Padwal R., Majumdar S.R., Johnson J.A., Varney J., McAlister F.A. Asystematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005, 28:736-744.
14. Savage P.J., Pressel S.L., Curb J.D., et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Int Med 1998, 158:741-751.
15. Kostis J.B., Wilson A.C., Freudenberger R.S., Cosgrove N.M., Pressel S.L., Davis B.R. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.
16. Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs. JHypertens 2006, 24:3-10.
17. Ostergren J., Poulter N.R., Sever P.S., et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. JHypertens 2008, 26:2103-2111.
18. Gupta A.K., Dahlof B., Dobson J., Sever P.S., Wedel H., Poulter N.R. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008, 31:982-988.
19. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
20. Weber M.A., Basile J., Stapff M., Khan B., Zhou D. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. JClin Hypertens (Greenwich) 2012, 14:588-592.
21. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003, 42:239-246.
22. Chapman N., Chen C.Y., Fujita T., et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension?. JHypertens 2010, 28:1796-1803.
23. Searle M., Dathan R., Dean S., Christensen C.C., Westheim A. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990, 39:299-300.
24. Poirier L., Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012, 28:334-340.